381 related articles for article (PubMed ID: 28658983)
21. Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma.
Boccadoro M; Palumbo A; Bringhen S; Merletti F; Ciccone G; Richiardi L; Rus C; Bertola A; Giaccone L; Omedè P; Musto P
Haematologica; 2002 Aug; 87(8):846-50. PubMed ID: 12161361
[TBL] [Abstract][Full Text] [Related]
22. Results of a phase I/II trial adding carmustine (300 mg/m2) to melphalan (200 mg/m2) in multiple myeloma patients undergoing autologous stem cell transplantation.
Comenzo RL; Hassoun H; Kewalramani T; Klimek V; Dhodapkar M; Reich L; Teruya-Feldstein J; Fleisher M; Filippa D; Nimer SD
Leukemia; 2006 Feb; 20(2):345-9. PubMed ID: 16319952
[TBL] [Abstract][Full Text] [Related]
23. A combination of anti-interleukin 6 murine monoclonal antibody with dexamethasone and high-dose melphalan induces high complete response rates in advanced multiple myeloma.
Moreau P; Harousseau JL; Wijdenes J; Morineau N; Milpied N; Bataille R
Br J Haematol; 2000 Jun; 109(3):661-4. PubMed ID: 10886221
[TBL] [Abstract][Full Text] [Related]
24. 200 mg/m(2) melphalan--the gold standard for multiple myeloma.
Giralt S
Nat Rev Clin Oncol; 2010 Sep; 7(9):490-1. PubMed ID: 20798699
[No Abstract] [Full Text] [Related]
25. Evolution of multiple myeloma treatment from melphalan monotherapy to bone marrow transplantation.
Hájek R; Adam Z; Vásová I; Král Z
Acta Med Austriaca; 1996; 23(3):85-91. PubMed ID: 8798281
[TBL] [Abstract][Full Text] [Related]
26. Melflufen: A Next-Generation Nitrogen Mustard.
Holstein SA; Hillengass J; McCarthy PL
J Clin Oncol; 2021 Mar; 39(7):836-839. PubMed ID: 33439689
[No Abstract] [Full Text] [Related]
27. Gelatinous transformation of bone marrow following chemotherapy for myeloma.
Mathew M; Mathews I; Manohar C; Rao S
Indian J Pathol Microbiol; 2001 Jan; 44(1):53-4. PubMed ID: 12561997
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of melphalan, arsenic trioxide, and ascorbic acid combination therapy (MAC) in relapsed and refractory multiple myeloma.
Borad MJ; Swift R; Berenson JR
Leukemia; 2005 Jan; 19(1):154-6. PubMed ID: 15496977
[No Abstract] [Full Text] [Related]
29. Rationale for adjuvant idiotypic vaccination after high-dose therapy for multiple myeloma.
Reichardt VL; Okada CY; Stockerl-Goldstein KE; Bogen B; Levy R
Biol Blood Marrow Transplant; 1997 Aug; 3(3):157-63. PubMed ID: 9310193
[TBL] [Abstract][Full Text] [Related]
30. [Cutaneous plasmacytomas following treatment of IgA kappa multiple myeloma].
Ortín X; Llorente A; Martínez S; Ugarriza A
Med Clin (Barc); 2004 Oct; 123(15):597-8. PubMed ID: 15535948
[No Abstract] [Full Text] [Related]
31. In focus: (166) Ho-DOTMP in the pretransplant treatment of multiple myeloma.
Clapp K
Clin Adv Hematol Oncol; 2004 Nov; 2(11):753-4. PubMed ID: 16170894
[TBL] [Abstract][Full Text] [Related]
32. Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma.
Morabito F; Tripepi G; Martino EA; Vigna E; Mendicino F; Morabito L; Todoerti K; Al-Janazreh H; D'Arrigo G; Canale FA; Cutrona G; Neri A; Martino M; Gentile M
Drug Des Devel Ther; 2021; 15():2969-2978. PubMed ID: 34262262
[TBL] [Abstract][Full Text] [Related]
33. Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma.
Palumbo A; Avonto I; Bruno B; Ambrosini MT; Bringhen S; Cavallo F; Falco P; Boccadoro M
Eur J Haematol; 2006 Apr; 76(4):273-7. PubMed ID: 16519697
[TBL] [Abstract][Full Text] [Related]
34. A case of melphalan sustained accumulation in an 80-year old patient.
Jolivot PA; Poinsignon V; Paci A; Guidet B; Pichereau C; Fernandez C; Hindlet P
Int J Clin Pharm; 2015 Dec; 37(6):984-7. PubMed ID: 26394785
[TBL] [Abstract][Full Text] [Related]
35. Researchers debate best use of stem cell transplants in patients with multiple myeloma.
Rowan K
J Natl Cancer Inst; 2009 Dec; 101(23):1608-11. PubMed ID: 19910555
[No Abstract] [Full Text] [Related]
36. IgE-type multiple myeloma with the late development of IgA2 kappa and plasma cell leukaemia.
Chiu W; Pullon H; Woon ST; Oei P; The R; Ameratunga R
Pathology; 2010 Jan; 42(1):82-4. PubMed ID: 20025486
[No Abstract] [Full Text] [Related]
37. [Multiple myeloma and other plasma cell dyscrasias].
del Potro Gómez E; Morales Sanz D
Rev Clin Esp; 1999 Apr; 199 Suppl 1():52-7. PubMed ID: 10422451
[No Abstract] [Full Text] [Related]
38. Induction therapy in a multiple myeloma mouse model using a combination of AS101 and melphalan, and the activity of AS101 in a tumor microenvironment model.
Hayun M; Saida H; Albeck M; Peled A; Haran-Ghera N; Sredni B
Exp Hematol; 2009 May; 37(5):593-603. PubMed ID: 19375650
[TBL] [Abstract][Full Text] [Related]
39. Stem cell mobilization in heavily pretreated multiple myeloma patients with prior high dose melphalan and auto-SCT.
Khaled Y; Al-Hazzouri A; Mizrachi A; Reynolds R; Reddy V; Solh M
Bone Marrow Transplant; 2013 Feb; 48(2):310-1. PubMed ID: 22773127
[No Abstract] [Full Text] [Related]
40. A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma.
Dispenzieri A; Wiseman GA; Lacy MQ; Litzow MR; Anderson PM; Gastineau DA; Tefferi A; Inwards DJ; Micallef IN; Ansell SM; Porrata L; Elliott MA; Lust JA; Greipp PR; Rajkumar SV; Fonseca R; Witzig TE; Erlichman C; Sloan JA; Gertz MA
Leukemia; 2005 Jan; 19(1):118-25. PubMed ID: 15526021
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
